Ken Cacciatore
Stock Analyst at TD Cowen
(0.38)
# 3,285
Out of 4,433 analysts
13
Total ratings
25%
Success rate
-31.19%
Average return
Main Sectors:
10 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $65 → $50 | $9.12 | +448.25% | 2 | Aug 9, 2023 | |
| BHC Bausch Health Companies | Downgrades: Market Perform | n/a | $7.07 | - | 1 | Jun 16, 2023 | |
| TAK Takeda Pharmaceutical | Maintains: Outperform | $30 → $20 | $13.31 | +50.26% | 3 | May 16, 2023 | |
| SCPH scPharmaceuticals | Initiates: Outperform | $25 | $4.83 | +418.13% | 1 | Dec 1, 2022 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $35 | $15.24 | +129.66% | 1 | May 11, 2022 | |
| MOLN Molecular Partners AG | Initiates: Outperform | n/a | $3.87 | - | 1 | Jul 13, 2021 | |
| TARA Protara Therapeutics | Initiates: Outperform | n/a | $3.74 | - | 1 | Oct 19, 2020 | |
| BHVN Biohaven Pharmaceutical Holding Company | Initiates: Outperform | n/a | $38.45 | - | 1 | Apr 17, 2020 | |
| AMRN Amarin Corporation | Initiates: Outperform | n/a | $0.91 | - | 1 | Mar 2, 2020 | |
| OPTN OptiNose | Initiates: Outperform | n/a | $1.29 | - | 1 | Dec 18, 2019 |
Arcutis Biotherapeutics
Aug 9, 2023
Maintains: Outperform
Price Target: $65 → $50
Current: $9.12
Upside: +448.25%
Bausch Health Companies
Jun 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $7.07
Upside: -
Takeda Pharmaceutical
May 16, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $13.31
Upside: +50.26%
scPharmaceuticals
Dec 1, 2022
Initiates: Outperform
Price Target: $25
Current: $4.83
Upside: +418.13%
Bausch + Lomb
May 11, 2022
Initiates: Outperform
Price Target: $35
Current: $15.24
Upside: +129.66%
Molecular Partners AG
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.87
Upside: -
Protara Therapeutics
Oct 19, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.74
Upside: -
Biohaven Pharmaceutical Holding Company
Apr 17, 2020
Initiates: Outperform
Price Target: n/a
Current: $38.45
Upside: -
Amarin Corporation
Mar 2, 2020
Initiates: Outperform
Price Target: n/a
Current: $0.91
Upside: -
OptiNose
Dec 18, 2019
Initiates: Outperform
Price Target: n/a
Current: $1.29
Upside: -